Swiss pharmaceutical company Myovant Sciences has created a subsidiary, Alyvant, to focus on sourcing personalised medications by connecting de-identified patient data with physician data via a technology platform. Roivant has been working on the acceleration of drug development and commercialisation using AI and data science technology through its subsidiaries, including Datavant.
Swiss pharmaceutical company Roivant Sciences has created a subsidiary, Alyvant, to focus on sourcing personalised medications by connecting de-identified patient data with physician data via a technology platform. Roivant has been working on the acceleration of drug development and commercialisation using AI and data science technology through its subsidiaries, including Datavant.